drugset / Trial / NCT01680250
Sirolimus for Massive Polycystic Liver
Phase 2/3
Unknown
44 enrolled
Seoul National University Hospital
Wyeth is now a wholly owned subsidiary of Pfizer · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the effectiveness and safety of Sirolimus in reducing liver volume in autosomal dominant polycystic kidney disease.
Timeline
- Start
- 2011-09
- Primary completion
- 2014-09
- Completion
- 2015-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sirolimus | Small molecule | 2 mg | Oral |